Mitchell Ho

Temporal mapping of the anti-tumor effects of nanobody-based MSLN.CAR-T cell therapy in metastatic solid tumors

This study tracks the temporal changes in the tumor microenvironment after nanobody-based CAR-T therapy, revealing dynamic gene expression shifts and identifying potential therapeutic targets.

Heparan Sulfate Controls Nanoscale Assembly of GPC3-Wnt Receptor Complexes

This study shows heparan sulfate regulates GPC3 nanoscale organization and Wnt receptor assembly in hepatoma cells, enhancing β-catenin signaling.

Engineering CAR T Cells for Hepatocellular Carcinoma Recurrence after Liver Transplantation

This paper develops GPC3-targeted CAR T cells resistant to immunosuppressive drugs and with reduced alloreactivity, showing efficacy in preclinical models and feasibility for clinical use post-liver transplantation.

Engineering Functionality-Optimized Fully Human B7-H3 CAR T Cells for Enhanced Solid Tumor Therapy

This study develops fully human B7-H3 CAR T cells using phage display, showing improved antitumor activity and reduced immune response in xenograft models.

Allogeneic CRISPR-Engineered CAR-T Cells Drive Potent Antitumor Activity in Solid Tumors

This study develops allogeneic CRISPR-engineered CAR-T cells targeting GPC2 and GPC3, showing potent antitumor activity in solid tumors with repeated dosing and no toxicity.

Enteroviral epitope mimicry enables NK cell-mediated targeting of ASPH in hepatocellular carcinoma

The paper identifies anti-CE1 antibodies that reduce HCC incidence and mortality by mediating NK cell ADCC against ASPH-expressing tumor cells through epitope mimicry.

Multimodal Approach for Identification and Validation of Hepatocellular Carcinoma Targets for Radiotheranostics

A multimodal pipeline defines and validates tumor-selective surface targets for radiotheranostic use in hepatocellular carcinoma.